220 related articles for article (PubMed ID: 33336229)
21. Non-invasive screening for Alzheimer's disease by sensing salivary sugar using Drosophila cells expressing gustatory receptor (Gr5a) immobilized on an extended gate ion-sensitive field-effect transistor (EG-ISFET) biosensor.
Lau HC; Lee IK; Ko PW; Lee HW; Huh JS; Cho WJ; Lim JO
PLoS One; 2015; 10(2):e0117810. PubMed ID: 25714733
[TBL] [Abstract][Full Text] [Related]
22. Accuracy of Biomarker Testing for Neuropathologically Defined Alzheimer Disease in Older Adults With Dementia.
Fink HA; Linskens EJ; Silverman PC; McCarten JR; Hemmy LS; Ouellette JM; Greer NL; Wilt TJ; Butler M
Ann Intern Med; 2020 May; 172(10):669-677. PubMed ID: 32340038
[TBL] [Abstract][Full Text] [Related]
23. Novel fluid biomarkers to differentiate frontotemporal dementia and dementia with Lewy bodies from Alzheimer's disease: A systematic review.
Chaudhry A; Houlden H; Rizig M
J Neurol Sci; 2020 Aug; 415():116886. PubMed ID: 32428759
[TBL] [Abstract][Full Text] [Related]
24. Longitudinal structural cerebral changes related to core CSF biomarkers in preclinical Alzheimer's disease: A study of two independent datasets.
Falcon C; Tucholka A; Monté-Rubio GC; Cacciaglia R; Operto G; Rami L; Gispert JD; Molinuevo JL;
Neuroimage Clin; 2018; 19():190-201. PubMed ID: 30023169
[TBL] [Abstract][Full Text] [Related]
25. Biomarkers for Alzheimer's disease: current status and prospects for the future.
Blennow K; Zetterberg H
J Intern Med; 2018 Dec; 284(6):643-663. PubMed ID: 30051512
[TBL] [Abstract][Full Text] [Related]
26. Testing the 2018 NIA-AA research framework in a retrospective large cohort of patients with cognitive impairment: from biological biomarkers to clinical syndromes.
Carandini T; Arighi A; Sacchi L; Fumagalli GG; Pietroboni AM; Ghezzi L; Colombi A; Scarioni M; Fenoglio C; De Riz MA; Marotta G; Scarpini E; Galimberti D
Alzheimers Res Ther; 2019 Oct; 11(1):84. PubMed ID: 31615545
[TBL] [Abstract][Full Text] [Related]
27. Cost-effectiveness of the use of biomarkers in cerebrospinal fluid for Alzheimer's disease.
Valcárcel-Nazco C; Perestelo-Pérez L; Molinuevo JL; Mar J; Castilla I; Serrano-Aguilar P
J Alzheimers Dis; 2014; 42(3):777-88. PubMed ID: 24916543
[TBL] [Abstract][Full Text] [Related]
28. Mass-Spectrometry-Based Method To Quantify in Parallel Tau and Amyloid β 1-42 in CSF for the Diagnosis of Alzheimer's Disease.
Pottiez G; Yang L; Stewart T; Song N; Aro P; Galasko DR; Quinn JF; Peskind ER; Shi M; Zhang J
J Proteome Res; 2017 Mar; 16(3):1228-1238. PubMed ID: 28112948
[TBL] [Abstract][Full Text] [Related]
29. 2020 update on the clinical validity of cerebrospinal fluid amyloid, tau, and phospho-tau as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework.
Leuzy A; Ashton NJ; Mattsson-Carlgren N; Dodich A; Boccardi M; Corre J; Drzezga A; Nordberg A; Ossenkoppele R; Zetterberg H; Blennow K; Frisoni GB; Garibotto V; Hansson O
Eur J Nucl Med Mol Imaging; 2021 Jul; 48(7):2121-2139. PubMed ID: 33674895
[TBL] [Abstract][Full Text] [Related]
30. Salivary tau species are potential biomarkers of Alzheimer's disease.
Shi M; Sui YT; Peskind ER; Li G; Hwang H; Devic I; Ginghina C; Edgar JS; Pan C; Goodlett DR; Furay AR; Gonzalez-Cuyar LF; Zhang J
J Alzheimers Dis; 2011; 27(2):299-305. PubMed ID: 21841250
[TBL] [Abstract][Full Text] [Related]
31. A two-step immunoassay for the simultaneous assessment of Aβ38, Aβ40 and Aβ42 in human blood plasma supports the Aβ42/Aβ40 ratio as a promising biomarker candidate of Alzheimer's disease.
Shahpasand-Kroner H; Klafki HW; Bauer C; Schuchhardt J; Hüttenrauch M; Stazi M; Bouter C; Wirths O; Vogelgsang J; Wiltfang J
Alzheimers Res Ther; 2018 Dec; 10(1):121. PubMed ID: 30526652
[TBL] [Abstract][Full Text] [Related]
32. Cerebrospinal fluid biomarkers for Alzheimer’s disease: diagnostic performance in a homogeneous mono-center population.
Johansson P; Mattsson N; Hansson O; Wallin A; Johansson JO; Andreasson U; Zetterberg H; Blennow K; Svensson J
J Alzheimers Dis; 2011; 24(3):537-46. PubMed ID: 21297262
[TBL] [Abstract][Full Text] [Related]
33. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment.
Mattsson N; Zetterberg H; Hansson O; Andreasen N; Parnetti L; Jonsson M; Herukka SK; van der Flier WM; Blankenstein MA; Ewers M; Rich K; Kaiser E; Verbeek M; Tsolaki M; Mulugeta E; Rosén E; Aarsland D; Visser PJ; Schröder J; Marcusson J; de Leon M; Hampel H; Scheltens P; Pirttilä T; Wallin A; Jönhagen ME; Minthon L; Winblad B; Blennow K
JAMA; 2009 Jul; 302(4):385-93. PubMed ID: 19622817
[TBL] [Abstract][Full Text] [Related]
34. Cerebrospinal Fluid Biomarkers in Idiopathic Normal Pressure Hydrocephalus versus Alzheimer's Disease and Subcortical Ischemic Vascular Disease: A Systematic Review.
Manniche C; Hejl AM; Hasselbalch SG; Simonsen AH
J Alzheimers Dis; 2019; 68(1):267-279. PubMed ID: 30741681
[TBL] [Abstract][Full Text] [Related]
35. Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease.
Palmqvist S; Zetterberg H; Mattsson N; Johansson P; ; Minthon L; Blennow K; Olsson M; Hansson O;
Neurology; 2015 Oct; 85(14):1240-9. PubMed ID: 26354982
[TBL] [Abstract][Full Text] [Related]
36. Alzheimer's cerebrospinal biomarkers from Lumipulse fully automated immunoassay: concordance with amyloid-beta PET and manual immunoassay in Koreans : CSF AD biomarkers measured by Lumipulse in Koreans.
Moon S; Kim S; Mankhong S; Choi SH; Vandijck M; Kostanjevecki V; Jeong JH; Yoon SJ; Park KW; Kim EJ; Yoon B; Kim HJ; Jang JW; Hong JY; Park DH; Shaw LM; Kang JH
Alzheimers Res Ther; 2021 Jan; 13(1):22. PubMed ID: 33436035
[TBL] [Abstract][Full Text] [Related]
37. Simultaneous analysis of cerebrospinal fluid biomarkers using microsphere-based xMAP multiplex technology for early detection of Alzheimer's disease.
Kang JH; Vanderstichele H; Trojanowski JQ; Shaw LM
Methods; 2012 Apr; 56(4):484-93. PubMed ID: 22503777
[TBL] [Abstract][Full Text] [Related]
38. Core candidate neurochemical and imaging biomarkers of Alzheimer's disease.
Hampel H; Bürger K; Teipel SJ; Bokde AL; Zetterberg H; Blennow K
Alzheimers Dement; 2008 Jan; 4(1):38-48. PubMed ID: 18631949
[TBL] [Abstract][Full Text] [Related]
39. Cerebrospinal Fluid Correlates of Neuropsychiatric Symptoms in Patients with Alzheimer's Disease/Mild Cognitive Impairment: A Systematic Review.
Showraki A; Murari G; Ismail Z; Barfett JJ; Fornazzari L; Munoz DG; Schweizer TA; Fischer CE
J Alzheimers Dis; 2019; 71(2):477-501. PubMed ID: 31424398
[TBL] [Abstract][Full Text] [Related]
40. Detection of amyloid beta peptides in body fluids for the diagnosis of alzheimer's disease: Where do we stand?
Veerabhadrappa B; Delaby C; Hirtz C; Vialaret J; Alcolea D; Lleó A; Fortea J; Santosh MS; Choubey S; Lehmann S
Crit Rev Clin Lab Sci; 2020 Mar; 57(2):99-113. PubMed ID: 31661652
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
